Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 301

Similar articles for PubMed (Select 23238036)

1.

The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.

Nygaard AD, Garm Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A.

Lung Cancer. 2013 Mar;79(3):312-7. doi: 10.1016/j.lungcan.2012.11.016. Epub 2012 Dec 11.

PMID:
23238036
2.

KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.

Mellema WW, Dingemans AM, Thunnissen E, Snijders PJ, Derks J, Heideman DA, Van Suylen R, Smit EF.

J Thorac Oncol. 2013 Sep;8(9):1190-5. doi: 10.1097/JTO.0b013e318298764e.

PMID:
23787801
3.

Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.

Dowler Nygaard A, Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A.

Oncol Rep. 2014 Feb;31(2):969-74. doi: 10.3892/or.2013.2906. Epub 2013 Dec 6.

PMID:
24316734
4.

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.

J Thorac Oncol. 2012 Oct;7(10):1490-502.

PMID:
22982650
5.

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.

Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward C, Mayne K, Trunzer K, Cappuzzo F.

J Clin Oncol. 2011 Nov 1;29(31):4113-20. doi: 10.1200/JCO.2010.31.8162. Epub 2011 Oct 3. Erratum in: J Clin Oncol. 2011 Dec 10;29(35):4725.

6.

Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.

Metro G, Chiari R, Bennati C, Cenci M, Ricciuti B, Puma F, Flacco A, Rebonato A, Giannarelli D, Ludovini V, Bellezza G, Ferolla P, Minotti V, Crinò L.

Clin Lung Cancer. 2014 Jan;15(1):86-92. doi: 10.1016/j.cllc.2013.08.002. Epub 2013 Oct 17.

PMID:
24139827
7.

Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?

Macerelli M, Caramella C, Faivre L, Besse B, Planchard D, Polo V, Ngo Camus M, Celebic A, Koubi-Pick V, Lacroix L, Pignon JP, Soria JC.

Lung Cancer. 2014 Mar;83(3):383-8. doi: 10.1016/j.lungcan.2013.12.013. Epub 2014 Jan 3.

PMID:
24439569
8.

A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer.

Cuffe S, Bourredjem A, Graziano S, Pignon JP, Domerg C, Ezzalfani M, Seymour L, Strevel E, Burkes R, Capelletti M, Jänne PA, Tsao MS, Shepherd FA.

J Thorac Oncol. 2012 Jun;7(6):963-72. doi: 10.1097/JTO.0b013e31824fe9e6.

9.

Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.

Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ.

Oncologist. 2012;17(1):13. doi: 10.1634/theoncologist.2011-0253. Epub 2011 Dec 30.

10.

KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.

Campos-Parra AD, Zuloaga C, Manríquez ME, Avilés A, Borbolla-Escoboza J, Cardona A, Meneses A, Arrieta O.

Am J Clin Oncol. 2015 Feb;38(1):33-40. doi: 10.1097/COC.0b013e318287bb23.

PMID:
23538866
11.

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.

Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, Dakhil S, Hermann RC, Lynch TJ, Weber MR.

J Clin Oncol. 2010 Feb 20;28(6):918-27. doi: 10.1200/JCO.2009.25.2890. Epub 2010 Jan 25.

12.

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.

J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.

13.

EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.

Mack PC, Holland WS, Burich RA, Sangha R, Solis LJ, Li Y, Beckett LA, Lara PN Jr, Davies AM, Gandara DR.

J Thorac Oncol. 2009 Dec;4(12):1466-72. doi: 10.1097/JTO.0b013e3181bbf239.

PMID:
19884861
14.

Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.

Schneider CP, Heigener D, Schott-von-Römer K, Gütz S, Laack E, Digel W, Guschall WR, Franke A, Bodenstein H, Schmidtgen C, Reck M.

J Thorac Oncol. 2008 Dec;3(12):1446-53. doi: 10.1097/JTO.0b013e31818ddcaa.

PMID:
19057271
15.

KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.

Smith JC, Brooks L, Hoff PM, McWalter G, Dearden S, Morgan SR, Wilson D, Robertson JD, Jürgensmeier JM.

Eur J Cancer. 2013 Jul;49(10):2424-32. doi: 10.1016/j.ejca.2013.02.023. Epub 2013 Mar 16.

PMID:
23510802
16.

Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.

Metro G, Chiari R, Duranti S, Siggillino A, Fischer MJ, Giannarelli D, Ludovini V, Bennati C, Marcomigni L, Baldi A, Giansanti M, Minotti V, Crinò L.

Lung Cancer. 2012 Oct;78(1):81-6. doi: 10.1016/j.lungcan.2012.06.005. Epub 2012 Jul 4.

PMID:
22770374
17.

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J.

J Clin Oncol. 2010 Nov 1;28(31):4706-13. doi: 10.1200/JCO.2009.27.6055. Epub 2010 Oct 4.

18.

Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.

Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR.

J Clin Oncol. 2010 Nov 1;28(31):4747-54. doi: 10.1200/JCO.2009.27.9356. Epub 2010 Oct 4.

19.

Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.

Sun JM, Hwang DW, Ahn JS, Ahn MJ, Park K.

PLoS One. 2013 May 28;8(5):e64816. doi: 10.1371/journal.pone.0064816. Print 2013.

20.

The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Fiala O, Pesek M, Finek J, Benesova L, Belsanova B, Minarik M.

Cancer Genet. 2013 Jan-Feb;206(1-2):26-31. doi: 10.1016/j.cancergen.2012.12.003. Epub 2013 Jan 10.

PMID:
23313110
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk